X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Last trade$3.04
Day change+$0.205 (+7.24%)
Day range$2.82 – $3.07
Volume768,026
Market cap$289M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$288.98M
Price / earnings
—
Price / book
2.08×
Price / sales
17.04×
EV / sales
10.62×
EV / EBITDA
-2.29×
Profitability
Earnings per share
-$0.79
Return on assets
-34.73%
Return on equity
-57.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.55×
Current ratio
13.22×
Quick ratio
12.86×
Cash ratio
12.4×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$76.1M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XFOR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.88M
$8.81M
$2.71M
$2.57M
$1.77M
$1.97M
$28.81M
$1.43M
Cost of revenue
$513K
$1.62M
$598K
$364K
$351K
$326K
$4.72M
$302K
Gross profit
$2.37M
$7.19M
$2.11M
$2.2M
$1.41M
$1.65M
$24.09M
$1.13M
Selling, general and administrative
$9.01M
$8.5M
$6.97M
$7.38M
$11.59M
$9.53M
$15.02M
$15.15M
Research and development
$13.34M
$15.08M
$15.45M
$18.52M
$17.34M
$18.35M
$18.51M
$21.7M
Total operating expenses
$22.36M
$23.58M
$22.42M
$25.9M
$28.92M
$27.88M
$33.53M
$36.85M
Operating income
-$19.99M
-$16.39M
-$20.31M
-$23.7M
-$27.51M
-$26.23M
-$9.44M
-$35.72M
Interest expense
-$2.19M
-$2.16M
-$2.13M
-$2.19M
-$2.26M
-$2.23M
-$2.2M
-$2.3M
Income before taxes
-$20.2M
-$16.16M
-$20.24M
-$23.93M
-$29.85M
-$25.7M
$316K
-$39.56M
Income taxes
$3K
$2K
$0
$0
-$30K
$37K
$34K
$258K
Net income
-$20.2M
-$16.16M
-$20.24M
-$23.93M
-$29.82M
-$25.74M
$282K
-$39.82M
Net income attributable to common shareholders
-$20.2M
-$16.16M
-$20.24M
-$23.93M
-$29.82M
-$25.74M
$282K
-$39.82M
EBITDA
-$19.66M
-$15.39M
-$20.08M
-$23.48M
-$27.29M
-$25.88M
-$8.97M
-$35.44M
Basic earnings per share
-$0.16
-$0.13
-$0.16
-$0.21
-$0.69
-$3.47
$0.04
-$5.89
Diluted earnings per share
-$0.16
-$0.13
-$0.16
-$0.21
-$0.69
-$3.47
$0.04
-$5.90
Recent news
Company coverage with links to the original publishers.
X4 Pharmaceuticals reported a quarterly loss of $0.16 per share, beating consensus estimates of $0.19 loss, with a 15.79% earnings surprise. The company posted revenues of $2.88 million, surpassing estimates by 43.95% and showing year-over-year growth. Despite underperforming the S&P 500 by 20.8% this year, the stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.
X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of mavorixafor (XOLREMDI) for treating WHIM syndrome in the EU. The drug, already FDA-approved in the U.S., would be the first and only therapy available in Europe for this ultra-rare immunodeficiency disorder. Final approval from the European Commission is anticipated in Q2 2026. X4 has partnered with Norgine for commercialization in Europe, Australia, and New Zealand, with potential milestone payments up to €226 million and royalties up to the mid-twenties.
X4 Pharmaceuticals announced a public offering of 45,860,000 shares and pre-funded warrants, expecting to raise approximately $135 million to fund Phase 3 development of mavorixafor for chronic neutropenic disorders.
Sitryx Therapeutics has appointed Adam Mostafa as its new Chief Financial Officer, bringing over 25 years of biotech financial experience, including previous roles at X4 Pharmaceuticals and Abpro Holdings.
X4 Pharmaceuticals secured a $60 million PIPE financing led by Coastlands Capital, with significant management and board leadership changes, including new appointments of Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as CFO.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.